Applied Proteomics said this week that it has closed a $28 million Series C financing round.
In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.
NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Protein biomarker diagnostics firm Astute Medical this week said it had completed a Series C financing round that raised $40.4 million.
By Adam Bonislawski
Applied Proteomics announced this week that it has appointed Peter Klemm as CEO and James Blair to its board of directors.
The company said it will use the money, which is an extension of a $26.5 million Series B round completed in May 2010, to advance and expand research, development, and validation of protein biomarker-based laboratory tests.
MBI plans to use the series B venture funding to develop its Apollo sample prep technologies.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.